MRTX1133   Click here for help

GtoPdb Ligand ID: 11851

Synonyms: compound 1 [PMID: 34889605] | MRTX-1133
PDB Ligand
Compound class: Synthetic organic
Comment: MRTX1133 is a selective, non-covalent inhibitor of the KRASG12D oncogene [2]. KRASG12D is the most common oncogenic mutation in KRAS mutated cancers. The chemical structure shown here was rendered from the SMILES string provided by Wang et al. in their disclosure paper [2]. Note that this rendering contains additional specified stereo centers compared to PubChem CID 156124857. Anti-tumour efficacy in relevant xenograft models was reported in October 2022 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 86.64
Molecular weight 600.63
XLogP 6.27
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C#Cc1c(F)ccc2c1c(cc(c2)O)c1ncc2c(c1F)nc(nc2N1C[C@@H]2CC[C@H](C1)N2)OC[C@]12CCCN2C[C@@H](C1)F
Isomeric SMILES [C@H]12CN(C[C@H](CC1)N2)c1c2c(nc(n1)OC[C@@]13CCCN1C[C@@H](C3)F)c(c(nc2)c1cc(cc2ccc(c(c12)C#C)F)O)F
InChI InChI=1S/C33H31F3N6O2/c1-2-23-26(35)7-4-18-10-22(43)11-24(27(18)23)29-28(36)30-25(13-37-29)31(41-15-20-5-6-21(16-41)38-20)40-32(39-30)44-17-33-8-3-9-42(33)14-19(34)12-33/h1,4,7,10-11,13,19-21,38,43H,3,5-6,8-9,12,14-17H2/t19-,20-,21+,33+/m1/s1
InChI Key SCLLZBIBSFTLIN-INOGPEIASA-N
Bioactivity Comments
MRTX1133 (via intraperitoneal administration) has demonstrated an anti-tumour effect in a KRASG12D mutant xenograft mouse model [2].
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
KRAS Hs Inhibitor Inhibition 12.7 pKd - 2
pKd 12.7 (Kd 2x10-13 M) [2]
Description: In vitro binding affinity for hKRASG12D by SPR